Veterinary Medicines

VANGUARD 7.

Authorised
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Canine distemper virus, strain N-CDV, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine parvovirus, strain NL-35-D, Live
Download as PDF

Product identification

Medicine name:
VANGUARD 7.
Active substance:
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Canine distemper virus, strain N-CDV, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine parvovirus, strain NL-35-D, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
    740.00
    unit(s)
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    915.00
    unit(s)
    /
    1.00
    millilitre(s)
  • Canine distemper virus, strain N-CDV, Live
    1000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan, Live
    1584.89
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    1000000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    10000000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Available in:
  • Ireland
Package description:
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-driedfraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap.Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and avarnished aluminium cap.Pack contains 100 vials of Vanguard DA2Pi freeze-dried fraction and 100 vials of 1 ml VanguardÔ CPV-L liquid fraction.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-driedfraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap.Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and avarnished aluminium cap.Pack contains 25 vials of Vanguard DA2Pi freeze-dried fraction and 25 vials of 1 ml VanguardÔ CPV-L liquid fraction.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-driedfraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap.Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and avarnished aluminium cap.Pack contains 10 vials of Vanguard DA2Pi freeze-dried fraction and 10 vials of 1 ml VanguardÔ CPV-L liquid fraction.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-driedfraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap.Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and avarnished aluminium cap.Pack contains 1 vial of Vanguard DA2Pi freeze-dried fraction and 1 vial of 1 ml VanguardÔ CPV-L liquid fraction.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10387/082/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."